Aibang Medicine has submitted an application to list on the Hong Kong Stock Exchange, marking a strategic shift from a research-focused entity to one driven by both research and commercial operations. The company specializes in innovative treatments for kidney diseases and related complications.
A key driver of this transition is the commercial success of Mircera® in China, which has significantly boosted revenue and improved gross margins. Additionally, the company's core candidate AP306 is advancing internationally through a partnership with R1 Therapeutics, establishing a global pathway that balances risk-sharing and long-term value creation.
Aibang Medicine's pipeline includes therapies for hyperphosphatemia, chronic kidney disease-related anemia, autosomal dominant polycystic kidney disease, and IgA nephropathy. The portfolio is structured in tiers, comprising a commercialized product, late-stage clinical assets, and preclinical programs.
The commercialization of Mircera®, the only once-monthly long-acting erythropoiesis-stimulating agent approved globally for CKD-related anemia, has been instrumental. Aibang holds exclusive commercialization rights for Mircera® in China. Since its launch in 2024, the product has been included in the National Reimbursement Drug List and is available in over 300 hospitals nationwide. Revenue surged by approximately 370% from 2024 to 2025, driven entirely by Mircera® sales. The company's gross margin also improved to 44.0% in 2025, up from 36.6% the previous year, reflecting cost optimizations from increased sales scale.
For its global strategy, AP306, an oral pan-phosphate transporter inhibitor for hyperphosphatemia, represents a cornerstone asset. The global hyperphosphatemia drug market was valued at $1.5 billion in 2024 and is projected to reach $6 billion by 2035. Unlike traditional phosphate binders, AP306 inhibits phosphate absorption via active transport mechanisms. Phase II trial data in China showed an average serum phosphorus reduction of 2.51 mg/dL, with nearly 95% of patients achieving controlled levels by week 7 or 8.
In December 2025, Aibang entered a collaboration and licensing agreement with R1 Therapeutics, granting R1 exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China. Aibang retains full rights in Greater China. The agreement includes potential milestone payments totaling up to several hundred million dollars, significant minority equity in R1, and tiered royalties on net sales exceeding $1 billion annually. This structure allows Aibang to share in long-term global value rather than conducting a one-time asset sale.
R1's recent $77.5 million Series A funding, led by Abingworth, DaVita Venture Group, and F-Prime Capital, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care, strengthens AP306's development prospects. DaVita and U.S. Renal Care together serve over 50% of the U.S. dialysis market, providing valuable clinical and market access resources. A global Phase IIb trial for AP306 is scheduled to begin in Q2 2026.
Meanwhile, Aibang's other core product, AP301, a phosphate binder for hyperphosphatemia in dialysis-dependent CKD patients, has completed Phase III trials in China. A New Drug Application submission to China's NMPA is expected in Q2 2026, with a global Phase III trial ongoing and an NDA planned with the U.S. FDA in Q3 2027.
To support pipeline advancement, Aibang increased its R&D expenditure to RMB 373 million in 2025, up 58.3% year-on-year. As of December 31, 2025, the company held cash and cash equivalents of approximately RMB 531 million. Proceeds from the IPO will fund clinical development, regulatory submissions, commercialization efforts for AP301 and Mircera®, upgrades to the Yangzhou production facility, and general working capital.
The company plans to establish a specialized sales team of 150-200 representatives following AP301's potential approval. With a commercial foundation established by Mircera®, a global collaboration model for AP306, and AP301 nearing regulatory submission, Aibang Medicine is positioning itself as an integrated renal disease innovation platform with both near-term commercial metrics and long-term global growth prospects.
Comments